Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | ASC4KIDS: investigating asciminib for pediatric patients with CML

Nobuko Hijiya • 6 Jun 2023
EHA 2023
Chronic Myeloid Leukemia Leukemia Asciminib Dasatinib Imatinib Nilotinib
ASC4KIDS

Nobuko Hijiya, MD, Columbia University Irving Medical Center, New York City, NY, discusses the rationale and aims of the ongoing Phase Ib/II ASC4KIDS study (NCT04925479), which is investigating dosage and safety of asciminib in pediatric patients with chronic myeloid leukemia (CML) in chronic phase. Children with CML often experience unique side effects which are especially seen during treatment with existing tyrosine kinase inhibitors (TKIs). Asciminb is a new class of drug, specifically targeting the ABL myristoyl pocket (STAMP), which has encouraging safety data from studies in adult patients with CML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nobuko Hijiya

3:19
Differences between CML in children and adults & the potential of asciminib in pediatric patients
Nobuko Hijiya • 6 Jun 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals